

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A2; B8, B38; Cw7, Cw12; DR17, DR13; DQ2, DQ6

Summary of Results					Summary of Results				
Total tested	24	24	22	24	15	15	14	15	
Positive	0	0	1	0	0	0	0	0	
Negative	24	24	21	24	15	15	14	15	
Not Tested / Equivocal	2	2	4	2	2	2	3	2	
% Positive	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%	
% Negative	100.0%	100.0%	95.5%	100.0%	100.0%	100.0%	100.0%	100.0%	
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	
HLA Antibody (Defined By CDC)	DQ3	A32,B44,DR7	Bw6	B7,DR2					

  

Lab No.	Without DTT				With DTT ( Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
117	Negative	Negative	Equivocal	Negative					
126	Negative	Negative	Negative	Negative					
136	Negative	Negative	Negative	Negative					
145	Negative	Negative	Negative	Negative					
162	Negative	Negative	Negative	Negative					
163	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
164	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
186	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	Negative	Negative	Negative	Negative					
227	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
235	Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	NT due to low cell viability
243	Negative	Negative	Negative	Negative					
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	NT	NT	NT	NT	NT	NT	NT	NT	Very low cell viability
259	Negative	Negative	Positive	Negative					
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Negative	Negative	Negative	Negative					
311	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
114	1	1	1	1	1	1	1	1	18-Sep	19-Sep		Yes	Yes		In-House	30	60	EB/AO
117	1	1		1					19-Sep	19-Sep	Yes		No	80	Pel-Freeze	60	120	Fluoroquench
126									17-Sep	18-Sep		Yes	Yes	100	Cedarlane	30	40	EB/AO
136	1	1	1	1					18-Sep	18-Sep	Yes		Yes	95	In-House	60	60	EB/AO
145									17-Sep	18-Sep		Yes	Yes	100	Invitrogen	45	45	EB/AO
162									17-Sep	18-Sep		Yes	Yes	100	Cedarlane	60	60	
163	1	1	1	1	1	1	1	1	17-Sep	17-Sep		Yes	Yes	98	Cedarlane	30	60	Fluoroquench
164									17-Sep	18-Sep		Yes	Yes	90	Servibio	45	90	Fluoroquench
169	1	1	1	1	1	1	1	1	18-Sep	19-Sep		Yes	No	97	One Lambda	35	75	Fluoroquench
186	0	0	0	0	0	0	0	0	17-Sep	17-Sep		Yes	Yes	98	Invitrogen	30	60	EB
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	1	1	1	1	1	1	1	17-Sep	17-Sep		Yes	No	90	Cedarlane	45	90	Fluoroquench
206	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes	95	Cedarlane	30	45	Fluoroquench
210	0	0	0	0	0	0	0	0	19-Sep	19-Sep		Yes	Yes	100	BioRad	30	60	
223	1	1	1	1					18-Sep	19-Sep		Yes	Yes	95	BioRad	45	60	EB/AO
227									17-Sep	17-Sep		Yes	Yes	97	Immucor	30	60	Fluoroquench
235	1	1	NT	1	1	1	NT	1	17-Sep	17-Sep	Yes		No	85	BioRad	30	60	
243	1	1	1	1					18-Sep	19-Sep	Yes		Yes	90	BioRad	30	60	Fluoroquench
245	2	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	Yes	Yes	100	BAG	30	60	EB/AO
252	NT	NT	NT	NT	NT	NT	NT	NT	18-Sep	08-Sep		Yes	Yes	20	One Lambda	30	60	
259									18-Sep	19-Sep	Yes	Yes	Yes	80	BioRad	30	60	AO/PI
268	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	No	80	Gentrak	30	60	EB/AO
284	1	1	1	1	1	1	1	1	17-Sep	18-Sep		Yes	Yes	98	Cedarlane	40	60	EB/AO
293									18-Sep	18-Sep		Yes	Yes	60	Invitrogen	60	120	Eosin
294	0	0	0	0					17-Sep	18-Sep		Yes	Yes		Pel-Freeze	30	30	Fluoroquench
311									17-Sep	17-Sep		Yes	Yes	100	Servibio	30	60	Fluoroquench

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1,A2; B8,B38; Cw7,Cw12; DR3,DR13; DQ2,DQ6

Summary of Results					Summary of Results				
Total tested	21	21	21	21	14	14	14	14	
Positive	1	0	2	1	1	0	1	0	
Negative	20	21	19	20	13	14	13	14	
Not Tested / Equivocal	2	2	2	2	2	2	2	2	
% Positive	4.8%	0.0%	9.5%	4.8%	7.1%	0.0%	7.1%	0.0%	
% Negative	95.2%	100.0%	90.5%	95.2%	92.9%	100.0%	92.9%	100.0%	
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	
HLA Antibody (Defined By CDC)	DQ3	A32,B44,DR7	Bw6	B7,DR2					

  

Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Negative					
145	Negative	Negative	Negative	Negative					
162	Negative	Negative	Negative	Negative					
163	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
164	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
186	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	Negative	Negative	Negative	Negative					
227	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
243	Negative	Negative	Negative	Weak Positive					
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	NT	NT	NT	NT	NT	NT	NT	NT	Very low cell viability
259	Negative	Negative	Positive	Negative					
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Negative	Negative	Negative	Negative					
311	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A09/2014 WB

DESPATCHED ON 16TH SEPTEMBER 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	1	1	1	1	1	1	1	18-Sep	19-Sep	Yes		One Lambda	30	60	EB/AO
126									17-Sep	18-Sep	Yes	75	Cedarlane	30	40	EB/AO
145									17-Sep	18-Sep	Yes	100	Invitrogen	45	45	EB/AO
162									17-Sep	18-Sep	Yes	80	Cedarlane	60	60	
163	1	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	98	Cedarlane	30	60	Fluoroquen
164									17-Sep	18-Sep	Yes	90	Servibio	45	90	Fluoroquen
169	1	1	1	1	1	1	1	1	18-Sep	19-Sep	Yes	97	One Lambda	35	75	Fluoroquen
186	0	0	4	0	0	0	2	0	17-Sep	17-Sep	Yes	92	Invitrogen	30	60	EB
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	95	Cedarlane	45	90	Fluoroquen
206	1	1	1	1	1	1	1	1	17-Sep	18-Sep	Yes	85	Cedarlane	30	45	Fluoroquen
210	0	0	0	0	0	0	0	0	19-Sep	19-Sep	Yes	80	BioRad	30	60	
223	2	2	2	2					18-Sep	19-Sep	Yes	80	BioRad	45	60	EB/AO
227									17-Sep	17-Sep	Yes	96	Immucor	30	60	Fluoroquen
243	1	1	1	4					18-Sep	19-Sep	Yes	90	BioRad	30	60	Fluoroquen
245	1	1	1	1	1	1	1	1	17-Sep	17-Sep	Yes	100	BAG	30	45	EB/AO
252	NT	NT	NT	NT	NT	NT	NT	NT	18-Sep	18-Sep	Yes	20	One Lambda	30	60	
259									18-Sep	19-Sep	Yes	80	BioRad	30	60	AO/PI
268	1	1	1	1	1	1	1	1	17-Sep	18-Sep	Yes	80	Gentrak	30	60	
284	1	1	1	1	1	1	1	1	17-Sep	18-Sep	Yes	87	Cedarlane	40	60	EB/AO
293									18-Sep	18-Sep	Yes	40	Invitrogen	60	120	Eosin
294	0	0	0	0					17-Sep	18-Sep			Pel-Freeze	30	30	
311									17-Sep	17-Sep	Yes	100	Servibio	30	60	Fluoroquen

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate